CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 41 enrolled
Drug / intervention
Omega-3 fatty acids (2.7 g/d, EPA:DHA, 2:1)dietary
Likely dose
Omega-3 fatty acids (2.7 g/d, EPA:DHA, 2:1)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04496154
NCT04496154N/ACompleted

The Inflammasome and Dysfunctional Adipose Tissue: Why Should apoB-lipoproteins be Targeted in Humans

May Faraj, PDt, PhD·interventional·Posted Aug 3, 2020·Updated Feb 11, 2025

In Brief

A clinical study evaluating Omega-3 fatty acids (2.7 g/d, EPA:DHA, 2:1) for Type 2 Diabetes and 3 related conditions. Completed, enrolled 41 participants.

Detailed Summary

In this project, investigators explored the role of the particles that carry "bad cholesterol" in the blood (termed LDL) that are known to promote heart disease, in the promotion of type 2 diabetes (T2D) in humans. In specific, they investigated how these particles may induce the activation of an immune pathway in human fat tissue leading to multiple anomalies that favors T2D. They also explored whether omega-3 fatty acids, which are the type of fat found in fish oils can counterbalance the negative effects of LDL in fat tissue, thus providing a natural way to help reduce the risk for T2D in subjects with elevated blood LDL. To do so, 41 subjects who were free of disease or medication affecting metabolism were enrolled at the Montreal Clinical Research Institute between 2013 and 2019 and were placed on an intervention with omega-3 fatty acids supplementation for 12 weeks (2.7 g/day, Triple Strength Omega-3 from Webbers Naturals). Investigators examined the effects of LDL and omega-3 on risk factors for T2D before and after the intervention in the whole body and specifically in fat tissue biopsies taken from the hip region. Eighty percent of the subjects who were enrolled into the study completed the intervention.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 3, 2020
Enrollment StartSep 5, 2013
Primary CompletionJan 22, 2020
Study CompletionFeb 24, 2020
TodayJul 2, 2026
Enrollment to primary: 6.4 yearsPosted 5.9 years ago

Interventions

Omega-3 fatty acids (2.7 g/d, EPA:DHA, 2:1)dietary

Triple Strength Omega-3 from Webber Naturals